Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

Last updated: August 31, 2025
Sponsor: Ebima Clifford Okundaye
Overall Status: Active - Not Recruiting

Phase

2/3

Condition

Focal Segmental Glomerulosclerosis

Nephropathy

Kidney Failure (Pediatric)

Treatment

QRX-3

Clinical Study ID

NCT06866236
0001
  • Ages 18-90
  • All Genders

Study Summary

Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study the investigators are using a novel drug to target improved function of the kidneys.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Inclusion criteria

  • Patient with Chronic kidney disease

  • Estimated Glomerular function by MDRD of less than 60mls/min

  • Patients with declining renal function ( as measured by eGFR by MDRD )

  • Rate of decline of eGFR over the last one year of less than 20%

  • Negative Serology markers for CKD etiology

  • Provider perceived adherence to study follow up

Exclusion

Exclusion Criteria:

Rapid rate of decline in kidney function of > 20 % over last one year

  • Symptomatic renal failure

  • Presence of any suspected Acute renal failure superimposed

  • Presence of cast , hematuria, or abnormal urinalysis outside of simple UTI

  • No known reversible cause of renal decline

Study Design

Total Participants: 3000
Treatment Group(s): 1
Primary Treatment: QRX-3
Phase: 2/3
Study Start date:
October 01, 2025
Estimated Completion Date:
July 31, 2027

Study Description

Chronic kidney disease has been linked to impaired activity of mitochondrial dysfunction along with oxidative intracellular mechanisms that result in the cascade of progressive damage within renal tubular cells. Several treatment options for mitochondrial dysfunction have been suggested to target the loss of nephrons via renal fibrosis and tubular senescence of the kidney cells by enhancing the mitochondrial activity of these cells via the NAD/NAD+ redox pathway as well as reduce the presence of fibrogenic intracellular inflammatory markers .

QRX-3 is a formulated novel drug designed to supply and optimize NAD+ mitochondrial availability and prevent this nephron loss .

In this study the investigators will evaluate the effect of intervention with this novel drug therapy on chronic kidney disease CKD population with slowly declining renal function.

Connect with a study center

  • Neukidney Inc

    Pasadena, Texas 77504
    United States

    Site Not Available

  • Neukidney Inc

    Pasedena, Texas 4736286 77504
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.